ALK is a tractable therapeutic focus on in neuroblastoma, probably to be inclined to equally smaller-molecule tyrosine kinase GPCR SIGNALING inhibitors and therapeutic antibodies---as has been demonstrated for other receptor tyrosine NF-κB Signaling kinases in malignancies these kinds of as breast and lung cancer.
